ID.1
Item
prostate cancer
boolean
C0007112 (UMLS CUI [1])
ID.2
Item
patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy)
boolean
C0194790 (UMLS CUI [1,1])
C0948317 (UMLS CUI [1,2])
ID.3
Item
patient was surgically or pharmacologically castrated at least 6 months prior to starting the study
boolean
C1319065 (UMLS CUI [1])
ID.4
Item
patient must have had a previous trial of anti-androgen therapy
boolean
C0279492 (UMLS CUI [1])
ID.5
Item
patient must have a rising psa
boolean
C0201544 (UMLS CUI [1])
ID.6
Item
no evidence of distant metastatic disease
boolean
C0027627 (UMLS CUI [1])
ID.7
Item
ecog performance status < 2
boolean
ID.8
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
ID.9
Item
patients must have normal hepatic function
boolean
C0232741 (UMLS CUI [1])
ID.10
Item
patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)
boolean
C0677881 (UMLS CUI [1,1])
C0203608 (UMLS CUI [1,2])
ID.11
Item
patients may not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1])
ID.12
Item
uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0012634 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
ID.13
Item
patients receiving renal dialysis
boolean
C0011946 (UMLS CUI [1])
ID.14
Item
patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded
boolean
C0024115 (UMLS CUI [1,1])
ID.15
Item
patients who have known hypersensitivity to any of the androgel ingredients, including testosterone that is chemically synthesized from soy
boolean
C0020517 (UMLS CUI [1,1])
C0875960 (UMLS CUI [1,2])